2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1488

Comparison Between Carotid Ultrasonography and Coronary Artery Calcification Score to Detect Subclinical Atherosclerosis in Rheumatoid Arthritis
Abstract Number: 1487

Comparison Between Intima-Media Thickness and Coronary Artery Tomography in Subclinical Atheroesclerosis Detection in Rheumatoid Arthritis
Abstract Number: 953

Comparison of 10-Years Disease Outcomes of Rheumatoid Arthritis Patients with Continued Low Disease Activity on Methotrexate with or without Initial Combination Therapy with Infliximab or Prednisone and Sulfasalazine
Abstract Number: 442

Comparison of Adherence and Dosing Interval of Subcutaneous Anti-TNF Biologics in Inflammatory Arthritis from a Canadian Administrative Database.
Abstract Number: 1728

Comparison of Adherence to Disease Modifying Antirheumatic Drugs in Psoriatic Arthritis and Other Rheumatic Disease
Abstract Number: 2242

Comparison of Assessment and Management of RA and Other Rheumatic Diseases By Rheumatologists in Private Practices or an Academic Medical Center
Abstract Number: 507

Comparison of Body Mass Index, Anti-Citrullinated Peptides Antibodies Status and Periodontal Condition in First Degree Relatives Individuals to Rheumatoid Arthritis
Abstract Number: 2987

Comparison of Certolizumab Pegol Versus Adalimumab: 2 Year Efficacy and Safety Results from a Superiority, Investigator-Blind, Head-to-Head Study
Abstract Number: 3093

Comparison of Changes in Cardiovascular Risk-Associated Biomarkers in RA Patients Treated with Anti-TNF or Other Biological Agents: A Metabolic Study from a Randomized Trial
Abstract Number: 2803

Comparison of Clinical and Serological Differences According to the Autoantibody Cluster in Women with Systemic Lupus Erythematosus: Results from the Korean Lupus Network (KORNET) Registry
Abstract Number: 2333

Comparison of Clinical Outcomes of Total Ankle Arthroplasty Between Biologics and NON-Biologics Treatment Groups in Patients with Rheumatoid Arthritis
Abstract Number: 1289

Comparison of Clinical Parameters and PET/MRI in Juvenile Idiopathic Arthritis
Abstract Number: 2755

Comparison of Clinical Profile of Geriatric and Non-Geriatric Ankylosing Spondylitis (AS) Patients
Abstract Number: 2249

Comparison of Discontinuation Rates Among Patients with RA Initiating Biologics
Abstract Number: 2464

Comparison of Disease Activity Score (DAS) 28-CRP to DAS28-ESR in Patients with Active Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].